# ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

> **NCT06922539** · PHASE1 · RECRUITING · sponsor: **SciTech Development, Inc.** · enrollment: 44 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Fenretinide
- **DRUG:** Fenretinide

## Key facts

- **NCT ID:** NCT06922539
- **Lead sponsor:** SciTech Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-11
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06922539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06922539, "ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT06922539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*